Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1)
Based on 2 publication(s) in Google Scholar
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived PD-L1 IgG1 κ type antibody inhibitor. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) increases IFN-γ levels in organoid-primed T cells. Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) can be used for the researches of cancer, such as oral squamous cell carcinoma and mammary cancer.
For research use only. We do not sell to patients.
- Purity : 99.406%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1)
More
Biological Activity
Description
Isotype
Mouse IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human/Mouse/Rat
IC50 & Target
PD-L1
In Vitro
In Vivo
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) (10 mg/kg, i.p., weekly for 6 weeks) significantly suppresses tumor growth in Nitroso-N-methylurea (NMU)-induced mammary tumor rats models[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:4-Nitroquinoline N-oxide (4NQO) (HY-33354)‑induced oral squamous cell carcinoma (OSCC) rats models (SD, male, 16 weeks)[1]
-
Dosage:200 μg/rat
-
Administration:Submucosally injection, twice a week at 16-20 week
-
Result:Alleviated mucosal lesions and the pathological impairment of OSCC.
Decreased CD8+T and CD11b cells.
-
Animal Model:Nitroso-N-methylurea (NMU) (HY-34758)-induced mammary tumor rats models (SD, female, 3-4 weeks)[2]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection, weekly for 6 weeks
-
Result:Significantly suppressed tumor growth.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
in vivo PD-L1 blockade; in vitro PD-L1 blockade; Flow cytometry
Verified Bioactivity
-
Flow cytometric analysis of 1X106 Jurkat cells with Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) (HY-P990173, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Mouse IgG H&L (HY-P8005) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Mouse IgG1 kappa (HY-P99977, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
-
Drug Resist Updat
RNF26 regulating tumor immunogenicity of hepatocellular carcinoma by degrading GRP78 and instigating ER stress. [Abstract]2026 Feb 8:86:101375. PMID: 41687462
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Goulet DR, Atkins WM. Considerations for the Design of Antibody-Based Therapeutics. J Pharm Sci. 2020 Jan;109(1):74-103. [Content Brief]
[2]. Zhou J, et al. Tumor-colonized Streptococcus mutans metabolically reprograms tumor microenvironment and promotes oral squamous cell carcinoma. Microbiome. 2024 Oct 5;12(1):193. [Content Brief]
[3]. Gil Del Alcazar CR, et al. Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer. Cancer Immunol Res. 2022 Jun 3;10(6):680-697. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)